We are live on
!
Find out more
Boston Partners Portfolio holdings
AUM
$95.5B
1-Year Est. Return
28.4%
This Fund
S&P 500
This Quarter
Est. Return
+8.8%
1 Year Est. Return
+28.4%
3 Year Est. Return
+84.58%
5 Year Est. Return
+116.72%
10 Year Est. Return
+426.49%
AUM
$83B
AUM Growth
+$4.08B
(+5.2%)
Cap. Flow
-$2.07B
Cap. Flow
% of AUM
-2.5%
Top 10 Holdings %
Top 10 Hldgs %
13.18%
Holding
730
New
59
Increased
161
Reduced
398
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Keurig Dr Pepper
KDP
|
+$550M |
| 2 |
Fidelity National Information Services
FIS
|
+$353M |
| 3 |
Global Payments
GPN
|
+$263M |
| 4 |
CVS Health
CVS
|
+$175M |
| 5 |
Devon Energy
DVN
|
+$150M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$433M |
| 2 |
Lowe's Companies
LOW
|
+$277M |
| 3 |
Oracle
ORCL
|
+$226M |
| 4 |
Progressive
PGR
|
+$220M |
| 5 |
Las Vegas Sands
LVS
|
+$167M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.96% |
| 2 | Healthcare | 15.3% |
| 3 | Industrials | 15.12% |
| 4 | Technology | 14.91% |
| 5 | Consumer Discretionary | 11.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APR
501
DELISTED
Apria, Inc. Common Stock
APR
| $1.29M | ﹤0.01% |
39,440
+19,504
| +98% | +$632K |
|
502
Zebra Technologies
ZBRA
$12.6B
| $1.28M | ﹤0.01% |
2,152
| – | – |
|
503
Henry Schein
HSIC
$9.64B
| $1.28M | ﹤0.01% |
16,501
| – | – |
|
504
Check Point Software Technologies
CHKP
$13.6B
| $1.26M | ﹤0.01% |
10,785
+1,456
| +16% | +$169K |
|
505
Universal Electronics
UEIC
$57.6M
| $1.24M | ﹤0.01% |
30,335
+6,898
| +29% | +$286K |
|
506
Open Text
OTEX
$5.73B
| $1.23M | ﹤0.01% |
25,817
| – | – |
|
507
Ennis
EBF
$550M
| $1.2M | ﹤0.01% |
61,624
-747
| -1% | -$14.4K |
|
508
Enova International
ENVA
$6.27B
| $1.2M | ﹤0.01% |
29,266
+4,560
| +18% | +$173K |
|
509
Lifecore Biomedical
LFCR
$163M
| $1.2M | ﹤0.01% |
107,693
+25,396
| +31% | +$246K |
|
510
Stellantis
STLA
$16.5B
| $1.16M | ﹤0.01% |
61,739
+2,930
| +5% | +$56.5K |
|
511
Barrett Business Services
BBSI
$995M
| $1.15M | ﹤0.01% |
66,720
| – | – |
|
512
Arcos Dorados Holdings
ARCO
$1.75B
| $1.15M | ﹤0.01% |
196,541
+47,827
| +32% | +$243K |
|
513
Perdoceo Education
PRDO
$1.99B
| $1.15M | ﹤0.01% |
97,433
+7,807
| +9% | +$85.1K |
|
514
Byline Bancorp
BY
$1.76B
| $1.14M | ﹤0.01% |
41,792
| – | – |
|
515
Super Micro Computer
SMCI
$19.3B
| $1.14M | ﹤0.01% |
258,780
| – | – |
|
516
Old Second Bancorp
OSBC
$1.27B
| $1.12M | ﹤0.01% |
88,879
+14,299
| +19% | +$188K |
|
517
Universal Insurance Holdings
UVE
$1.21B
| $1.12M | ﹤0.01% |
65,713
| – | – |
|
518
Axcelis
ACLS
$3.94B
| $1.11M | ﹤0.01% |
14,839
-47,450
| -76% | -$2.81M |
|
519
Ezcorp Inc
EZPW
$1.87B
| $1.1M | ﹤0.01% |
149,595
+2,955
| +2% | +$22.4K |
|
520
Vanguard Extended Market ETF
VXF
$30.5B
| $1.1M | ﹤0.01% |
+6,009
| New | +$1.13M |
|
|
AMED
521
DELISTED
Amedisys
AMED
| $1.09M | ﹤0.01% |
6,751
-679
| -9% | -$109K |
|
522
Capital Bancorp
CBNK
$591M
| $1.08M | ﹤0.01% |
41,322
| – | – |
|
523
First Interstate BancSystem
FIBK
$3.67B
| $1.07M | ﹤0.01% |
26,434
-269
| -1% | -$11.2K |
|
524
Virtu Financial
VIRT
$5.12B
| $1.07M | ﹤0.01% |
36,965
+2,545
| +7% | +$69.4K |
|
525
Quanta Services
PWR
$93.1B
| $1.04M | ﹤0.01% |
9,089
-7,675
| -46% | -$885K |
|
Similar funds
Boston Partners's Q4 2021 Portfolio in Review
As of Q4 2021, Boston Partners held 730 positions worth $83B, up 5.2% from $78.9B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Boston Partners's Q4 2021 filing shows 59 new, 161 increased, 398 reduced and 45 closed positions. Its largest new stake was Keurig Dr Pepper: 15,605,496 shares worth $575M. The largest sale was Pfizer, an estimated $433M.
By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 22% a quarter earlier, followed by Healthcare and Industrials.
- Boston Partners's largest Q4 2021 buy was Keurig Dr Pepper: 15,605,496 shares worth $575M.
- Boston Partners added most to Fidelity National Information Services in Q4 2021, an estimated $353M increase.
- Boston Partners's biggest Q4 2021 reduction was Pfizer, cutting an estimated $433M.
- Boston Partners fully exited CyrusOne Inc Common Stock in Q4 2021, selling an estimated $137M.
- Boston Partners's ten largest holdings make up 13% of its $83B portfolio in Q4 2021.
- Boston Partners opened 59 new positions and closed 45 in Q4 2021.
- Boston Partners's portfolio value rose 5.2% quarter-over-quarter to $83B.
Based on Boston Partners's 13F filing for Q4 2021, filed 4 Feb 2022.